References
- Wendling D, Toussirot E. Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin. Pharmacother. 5(7), 1497–1507(2004).
- Furst DE, Keystone EC, So AK et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann. Rheum. Dis. 72(Suppl. 2), ii2–ii3 (2013).
- Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin. Rheumatol. 26(2), 211–215 (2007).
- Gratacós J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. J. Rheumatol. 33(10), 927–931 (1994).
- François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann. Rheum. Dis. 65(6), 713–720 (2006).
- Wendling D. Interleukin-6 as a therapeutic target in spondylarthritis: comment on the article by Tanaka et al. Arthritis Care Res. (Hoboken) 62(5), 745 (2010).
- Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response totocilizumab for ankylosing spondylitis. Ann. Rheum. Dis. 69(12), 2217–2218 (2010).
- Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 77(6), 625–626 (2010).
- Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 77(6), 624–625(2010).
- Shima Y, Tomita T, Ishii T et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod. Rheumatol. 21(4), 436–439 (2011).
- Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J. Rheumatol. 38(7), 1527 (2011).
- Dudler J, Aubry-Rozier B. Tocilizumab in axial spondylarthropathies: about 18 cases [OP0178]. Ann. Rheum. Dis. 70(Suppl. 3), 128 (2011).
- Gossec L, Del Castillo-Piñol N, Roux C, Dougados M. Lack of efficacy of tocilizumab in severe axial refractory spondyloarthritis: a report of 5 patients. Clin. Exp. Rheumatol. 30(5), 805 (2012).
- Lekpa FK, Poulain C, Wendling D et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res. Ther. 14(2), R53 (2012).
- Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. (2013) (Epub ahead of print).
- Sieper J, Inman R.D., Badalamenti S et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. double-blind, placebo-controlled, international study (ALIGN) [OP0169]. Ann. Rheum. Dis. 71(Suppl. 3), 111 (2012).
- Wendling D, Prati C. Biologic agents for treating ankylosing spondylitis: beyond TNFalpha antagonists. Joint Bone Spine 78(6), 542–544 (2011).
- Wendling D. Are there new emerging drugs for ankylosing spondylitis orspondyloarthritis? Expert Opin. Emerg. Drugs 18(1), 5–7 (2013).
- Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol. Int. 30(11), 1547 (2010).
- Sherlock JP, Cua DJ. Interleukin-23: a promising therapeutic target in seronegativespondyloarthropathy. Curr. Opin. Pharmacol. 13(3), 445–448 (2013).
- Carter S, Braem K, Lories RJ. The role of bone morphogenetic proteins in ankylosing spondylitis. Ther. Adv. Musculoskelet. Dis. 4(4), 293–299 (2012).